

12-Lipoxygenase
12-lipoxygenase (12-LOX) is an enzyme that oxidizes fatty acids, generates proinflammatory metabolites and has been implicated in a myriad of diseases including Heparin-Induced Thrombocytopenia (HIT) and Type 1 Diabetes (T1D). We are developing therapies for these diseases with a clinical program in HIT, preclinical program in T1D and discovery research aimed at expanding our 12-LOX inhibitors to additional diseases.
Learn More about the Target

Heparin-Induced Thrombocytopenia (HIT)
HIT is a deadly syndrome characterized by hyperactivated platelets and a devastating pro-thrombotic state. Targeting 12-LOX inhibits the production of 12-HETE, a proinflammatory metabolite known to play a role in platelet activation and thrombosis. We received Orphan Designation and Fast Track Designation for our first-in-class drug product, VLX-1005, addressing the underlying cause of this immune-driven blood clotting.
Learn More

Type 1 Diabetes (T1D)
We are developing a disease-modifying therapy for T1D. By inhibiting 12-LOX and shutting down production of its products like 12-HETE, β cells are able to function properly by producing more insulin and becoming more resilient to immune attack.
Learn MoreMeet the Team
Recent News

Veralox Therapeutics Announces Favorable Results of Phase 1 Studies of VLX-1005 in Development for Treatment of Heparin-Induced Thrombocytopenia
Development program for VLX-1005, a novel small molecule 12-LOX inhibitor, awarded Fast Track designation by US Food and Drug Administration FREDERICK, Md., June 13, 2022 — Veralox Therapeutics, a biotechnology … Read More
Veralox Therapeutics Appoints Lisa Beck as Chief Business Officer
Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Lisa Beck as … Read More
Veralox Therapeutics Appoints Michael Hanna As Chief Medical Officer
Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Michael S. Hanna, … Read More